Gastric/Gastroesophageal Junction Cancer Clinical Trial
Official title:
Phase II Study of Evaluating Efficacy, Safety and Tolerance of KN026 in HER2 Expressing Advanced Gastric/Gastroesophageal Junction Cancer
This is an open-label, phase 2 study of KN026 in subjects with HER2 expressing gastric/gastroesophageal junction cancer to evaluate efficacy and safety. The subjects will receive KN026 10 mg/kg QW or 20 mg/kg Q2W or 30mg/kg Q3W until progressive disease, unacceptable toxicity or death.
The study consists of two arms as HER2 overexpression arm and HER2 expression arm and both arms will receive KN026 treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03847168 -
KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer
|
Phase 1 | |
| Completed |
NCT03941873 -
A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) or Gastric/Gastroesophageal Junction Cancer (GC/GEJC)
|
Phase 1/Phase 2 |